pgp3 markers of chlamydia in HIV
This article was originally published in Clinica
Executive Summary
Testing for pgp3 could be an effective way to screen HIV and STD patients in studies on chlamydia-HIV interaction. Researchers from Laboratories of the HCM Chlamydia Network of the European Community, Amiens (France) and IRIS Research Centre, Chiron-Biocine Siena (Italy) report in The Lancet (September 20th) that they found an unexpectedly high prevalence (83%) of pgp3-positive responses in CtMIF-negative patients.